Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system.  NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states.  Targacept’s clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities.  Targacept leverages its scientific leadership and diverse pipeline to attract significant collaborations with global pharmaceutical companies.  For more information, please visit www.targacept.com.

Life Sciences

Therapeutics

Targacept, Inc.

Org chart

Similar companies